Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Climara Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Premarin Versus Toviaz for Treatment of Overactive Bladder

NCT01613170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Toviaz, Premarin, Placebo cream
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 100 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

NCT02817841
View directory record Official record
Conditions
Contraception
Interventions
15 mg E4/3 mg DRSP
Drug
Lead sponsor
Estetra
Industry
Eligibility
16 Years to 50 Years · Female only
Enrollment
2,148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 21, 2026, 5:21 AM EDT
Not listed Phase 2 Interventional

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

NCT00003066
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Oral Contraceptive Pill (OCP)

NCT01063023
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Ortho Tri-Cyclen®, BMS-650032
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

NCT06380205
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Levonorgestrel/Ethinyl estradiol
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT00608062
View directory record Official record
Conditions
Arterial Stiffening, Aging, Menopause
Interventions
GnRHant - Ganirelix acetate, Transdermal estradiol patch, Transdermal placebo patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

NCT01427595
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism
Interventions
Metformin, Progesterone, estrace
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 21, 2026, 5:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endometriosis and Migraine

NCT06785129
View directory record Official record
Conditions
Migraine, Endometriosis
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Conditioned pain modulation (CPM) response, Hormonal assessment
Device · Behavioral · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Menopause Effects on Vascular Function

NCT03236545
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
No to Low Endogenous Estrogen, Estradiol
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

NCT01441947
View directory record Official record
Conditions
Breast Cancer
Interventions
Cabozantinib, Fulvestrant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 21, 2026, 5:21 AM EDT
Recruiting Phase 3 Interventional

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

NCT07100782
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Relugolix CT
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

NCT01178125
View directory record Official record
Conditions
Contraception, Female Contraception
Interventions
DR-102
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
2,858 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
52
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 21, 2026, 5:21 AM EDT
Not listed Phase 2 Interventional

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00003717
View directory record Official record
Conditions
Prostate Cancer
Interventions
estramustine phosphate sodium, paclitaxel
Drug
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Livingston, New Jersey • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 21, 2026, 5:21 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

NCT04856306
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Fibroid Uterus
Interventions
Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
Other · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 21, 2026, 5:21 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Advancing Postmenopausal Preventive Therapy

NCT04103476
View directory record Official record
Conditions
Atherosclerosis, Cognitive Decline
Interventions
Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg, Placebo
Combination Product · Other
Lead sponsor
University of Southern California
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03271489
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
155
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 4 Interventional Results available

Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality

NCT03498313
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Transdermal Estradiol + Placebo, Oral Micronized Progesterone + Placebo, Placebos
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 21, 2026, 5:21 AM EDT
Terminated Phase 1 Interventional

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

NCT07408089
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
BBI-940, Fulvestrant
Drug
Lead sponsor
Boundless Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Los Angeles, California • Lake Success, New York • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

NCT03126097
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64155806 150 mg, Ethinylestradiol/drospirenone 0.02 mg/3 mg, COCP Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

NCT02953860
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant with Enzalutamide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Lone Tree, Colorado • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 21, 2026, 5:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917
View directory record Official record
Conditions
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions
AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 5:21 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 21, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women

NCT03681691
View directory record Official record
Conditions
Diabetes Type 2, Dementia
Interventions
Estradiol patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 21, 2026, 5:21 AM EDT